Prilenia is a private biopharmaceutical company dedicated to developing transformative medicines for individuals affected by neurodegenerative diseases. With a strong commitment to scientific excellence, Prilenia is focused on advancing its investigational therapy, pridopidine, a unique oral sigma-1 receptor agonist aimed at treating ALS and Huntington's disease. The company collaborates with Ferrer for the commercialization and co-development of pridopidine and is preparing to initiate late-stage clinical trials to support global approval in the near future. Prilenia prides itself on its talented global team and a culture that fosters innovation and operational excellence.